header
  • Home
  • Company Info
    • Management Team
    • Bor-Wen Wu, PhD MBA
    • John Bomalaski, MD
    • Archie Prestayko, PhD
    • W. Jenny Kung, PhD
    • Wei He, PhD
    • Jim Thomson, PhD
    • Steve Wu
    • Advisory Board
    • Lloyd J. Old, MD
    • Steven A. Curley, MD
    • George Demetri, MD
    • Robert C. Jackson, PhD
    • Hsing-Jien Kung, MD PhD
    • Jedd D. Wolchok, MD PhD
    • Subsidiaries
    • Polaris Pharmaceuticals
    • TDW Pharmaceuticals
    • DRX Pharmaceuticals
    • DRX (Shanghai)
  • Pipeline
    • ADI-PEG 20 (Oncology)
    • About Metastatic Melanoma
    • About Hepatocellular Carcinoma
    • Uricase-PEG 20
    • About Hyperuricemia
    • About Gout
    • About Tumor Lysis Syndrome
    • TNF-PEG 20
    • CK2 Inhibitor
    • ADI-PEG 20 (Antiviral)
    • About Hepatitis C Virus
    • Histidase-PEG 20
  • Collaborations
    • Ludwig Institute for Cancer Research
    • Cleveland Clinic
    • South Florida VA Foundation
    • University of California - Davis
    • National Taiwan University
    • Barts and the London School of Medicine and Dentistry
  • Literature
    • Polaris & Collaborators
    • ADI-PEG 20 (oncology)
    • Uricase-PEG 20:
    • TNF-PEG 20:
    • CK2 inhibitor:
    • ADI-PEG 20 (antiviral):
    • Related Publications
    • ADI general:
    • ADI (oncology) renal cell carcinoma:
    • ADI (oncology) combination therapy:
    • TNF cancer treatment:
    • CK2 inhibitor:
    • Histidase cancer treatment:
  • Company News
  • Contact
  • Literature
  • Polaris & Collaborators
  • ADI-PEG 20 (oncology)
  • Uricase-PEG 20:
  • TNF-PEG 20:
  • CK2 inhibitor:
  • ADI-PEG 20 (antiviral):
  • Related Publications
  • ADI general:
  • ADI (oncology) renal cell carcinoma:
  • ADI (oncology) combination therapy:
  • TNF cancer treatment:
  • CK2 inhibitor:
  • Histidase cancer treatment:
  • ADI-PEG 20 (oncology) general:
  • ADI-PEG 20 (oncology) hepatocellular carcinoma:
  • ADI-PEG 20 (oncology) melanoma:
  • ADI-PEG 20 (oncology) mesothelioma:
  • ADI-PEG 20 (oncology) ovarian cancer:
  • ADI-PEG 20 (oncology) pancreatic cancer:
  • ADI-PEG 20 (oncology) prostate cancer:

Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis

R.H. Kim, J.M. Coates, T.L. Bowles, G.P. McNerney, J. Sutcliffe, J.U. Jung, R. Gandour-Edwards, F.Y. Chuang, R.J. Bold, and H.J. Kung
Cancer Research (2009), Vol. 69 pages 700-708

ADI, autophagy, and apoptosis: metabolic stress as a therapeutic option for prostate cancer

R.H. Kim, R.J. Bold, H.J. Kung
Autophagy (2009), Vol. 5 pages 567-568

© Copyright The Polaris Group. All rights reserved.